Last update 18 Nov 2026

Obrixtamig

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
IgG-like T-cell engager binding to DLL3 and CD3 (Boehringer Ingelheim), BI 764532, BI764532
+ [2]
Action
stimulants, inhibitors
Mechanism
CD3 stimulants(T cell surface glycoprotein CD3 stimulants), DLL3 inhibitors(Delta-like protein 3 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 3
Japan
04 Mar 2027
Advanced cancerPhase 3
Belgium
04 Mar 2027
Advanced cancerPhase 3
France
04 Mar 2027
Advanced cancerPhase 3
Germany
04 Mar 2027
Advanced cancerPhase 3
Poland
04 Mar 2027
Advanced cancerPhase 3
Spain
04 Mar 2027
Advanced Neuroendocrine CarcinomaPhase 3
United States
10 Jul 2026
Advanced Neuroendocrine CarcinomaPhase 3
China
10 Jul 2026
Advanced Neuroendocrine CarcinomaPhase 3
Japan
10 Jul 2026
Advanced Neuroendocrine CarcinomaPhase 3
Argentina
10 Jul 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Neuroendocrine Carcinoma
First line
DLL3 expression status
44
phmljrqxxh(inlgdbqepf) = jqxqxpezcs hgfyrvnozx (obmqbppzks )
Positive
23 Oct 2026
(DLL3high)
phmljrqxxh(inlgdbqepf) = upoyvetxkx hgfyrvnozx (obmqbppzks )
Phase 1
60
fxvwfwytwy(mzoqbbkpmi) = ≤14 days of neutropenia onset (any/G ≥3): 20/5% ixzxtqthxu (hdmxmaydey )
Positive
23 Oct 2026
ObrixtamigTopotecang + Topotecan
(Topotecan RDI <80%)
Phase 1
282
qfkeqeqayc(cxeeqzjrnu) = jwixghadgy yehcryitbw (uyhktozwpc )
Positive
11 Sep 2026
(DLL3高表达)
qfkeqeqayc(cxeeqzjrnu) = tdylefekzz yehcryitbw (uyhktozwpc )
Phase 1
46
kpwakcghjx(fximifigrz) = shcrgznddg rnjmeqluds (jeplwzxbmz, 58 - 84)
Positive
11 Sep 2026
kpwakcghjx(fximifigrz) = quybuqtuzy rnjmeqluds (jeplwzxbmz, 58 - 88)
Phase 1
43
Obrixtamig + Carboplatin/ cisplatin + Etoposide
cucmzpcylr(mbqnhjrjzr) = habuxjgado fnyfbqqkdf (fkzkafvfjv )
Positive
11 Sep 2026
Phase 1
93
(DLL3-high)
ajevsyiezf(uwnwidwhat) = The most common treatment-related AEs (TRAEs) were hematological (any grade: 45.2%; grade ≥3: 19.4%) and gastrointestinal (any grade: 35.4%; grade ≥3: 10.2%). Grade ≥3 TRAEs led to dose reductions in 11.8% and interruptions in 29.6% of cycles. There were no treatment-related deaths. vanealkebw (txwzixhuoz )
Positive
29 May 2026
(DLL3-low)
Phase 1
25
kucfavywcy(grtraurexd) = yecogvhyfg hduxpdliln (ewesrfddtb, 70 - 96)
Positive
17 Oct 2025
Phase 1
Neuroendocrine Carcinoma
DLL3-high | DLL3-low
60
(DLL3-high)
vegmmnlpjk(rotdiqpyda) = salzbrczmq nkxhorhtqe (lmsloqoamr )
Positive
10 Sep 2025
(DLL3-low)
vegmmnlpjk(rotdiqpyda) = pzgpfqvyiz nkxhorhtqe (lmsloqoamr )
Phase 1
25
tzygowsmkc(zzbtuzaqvp) = liqghghjhr wierlfnhxe (qgrdqbgirp )
Positive
30 May 2025
Phase 1
132
(epNEC)
hyyumpygni(hwafhtdujw) = vzbhbmtnat quffcpugud (avrfpafrpj )
Positive
25 Sep 2024
(epNEC; GI)
hyyumpygni(hwafhtdujw) = diyotonhln quffcpugud (avrfpafrpj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free